OTCMKTS:INNV InnovAge (INNV) Stock Forecast, Price & News $7.86 +0.19 (+2.48%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$7.33▼$7.9950-Day Range$5.74▼$7.9852-Week Range$3.39▼$8.15Volume47,613 shsAverage Volume32,219 shsMarket Capitalization$1.07 billionP/E RatioN/ADividend YieldN/APrice Target$7.25 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort Interest InnovAge MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside7.8% Downside$7.25 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment1.52Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.25) to ($0.05) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.0.91 out of 5 stars 1.0 Analyst's Opinion Consensus RatingInnovAge has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.25, InnovAge has a forecasted downside of 7.8% from its current price of $7.86.Amount of Analyst CoverageInnovAge has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for INNV. Previous Next 0.0 Dividend Strength Dividend YieldInnovAge does not currently pay a dividend.Dividend GrowthInnovAge does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INNV. Previous Next 3.1 News and Social Media Coverage News SentimentInnovAge has a news sentiment score of 1.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for InnovAge this week, compared to 1 article on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, InnovAge insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.25% of the stock of InnovAge is held by insiders.Percentage Held by InstitutionsOnly 12.44% of the stock of InnovAge is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for InnovAge are expected to grow in the coming year, from ($0.25) to ($0.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of InnovAge is -25.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of InnovAge is -25.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInnovAge has a P/B Ratio of 3.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About InnovAge (OTCMKTS:INNV) StockInnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in their homes and communities. It manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. The company offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the PACE center and third-party medical appointments; and care management. As of June 30, 2022, it served approximately 6,650 PACE participants in the United States; and operates 18 PACE centers in Colorado, California, New Mexico, Pennsylvania, and Virginia. The company was formerly known as TCO Group Holdings, Inc. and changed its name to InnovAge Holding Corp. in January 2021. InnovAge Holding Corp. was founded in 2007 and is headquartered in Denver, Colorado.Read More Receive INNV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InnovAge and its competitors with MarketBeat's FREE daily newsletter. Email Address INNV Stock News HeadlinesJune 5, 2023 | finance.yahoo.comInnovAge Announces Participation at the 44th Annual Goldman Sachs Global Healthcare ConferenceMay 13, 2023 | americanbankingnews.comInnovAge (OTCMKTS:INNV) Price Target Cut to $7.00 by Analysts at CitigroupJune 7, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 11, 2023 | msn.comRecap: InnovAge Holding Q3 EarningsMay 11, 2023 | finance.yahoo.comInnovAge Holding Third Quarter 2023 Earnings: EPS Misses ExpectationsMay 10, 2023 | bizjournals.comInnovAge points to small but steady signs of growth after release from final sanctionsMay 10, 2023 | finance.yahoo.comInnovAge Holding Corp. (INNV) Reports Q3 Loss, Lags Revenue EstimatesMay 9, 2023 | finance.yahoo.comInnovAge Announces Financial Results For The Fiscal Third Quarter Ended March 31, 2023June 7, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 8, 2023 | markets.businessinsider.comWhat Wall Street expects from InnovAge's earningsMay 1, 2023 | finance.yahoo.comFinal Sanction Removed at InnovAge Sacramento PACE Center Enabling New Participant EnrollmentApril 25, 2023 | finance.yahoo.comInnovAge to Announce Fiscal Third Quarter 2023 Financial Results and Host Conference Call Tuesday, May 9, 2023April 17, 2023 | finance.yahoo.comNot Many Are Piling Into InnovAge Holding Corp. (NASDAQ:INNV) Just YetApril 9, 2023 | americanbankingnews.comInnovAge (OTCMKTS:INNV) Shares Cross Above Fifty Day Moving Average of $7.21March 30, 2023 | finance.yahoo.comInnovAge Diversifies Board of Directors with New Independent DirectorMarch 9, 2023 | finance.yahoo.comInnovAge Holding Corp. (INNV) Loses -7.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerMarch 1, 2023 | finance.yahoo.comInnovAge Names Christine Bent as Chief Operations OfficerFebruary 10, 2023 | finance.yahoo.comInnovAge Holding Corp. (NASDAQ:INNV) Q2 2023 Earnings Call TranscriptJanuary 24, 2023 | finance.yahoo.comInnovAge to Announce Fiscal Second Quarter 2023 Financial Results and Host Conference Call Tuesday, February 7, 2023January 24, 2023 | finance.yahoo.comInnovAge released from sanctions, can enroll Colorado patients once moreJanuary 23, 2023 | finance.yahoo.comState and Federal Regulators Lift Sanctions at InnovAge’s Colorado PACE CentersJanuary 5, 2023 | finance.yahoo.comInnovAge Announces Participation at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 14, 2022 | finance.yahoo.comShareholders in InnovAge Holding (NASDAQ:INNV) have lost 14%, as stock drops 5.6% this past weekNovember 22, 2022 | finance.yahoo.comInnovAge Announces Release of CMS Sanction in Sacramento CenterNovember 8, 2022 | finance.yahoo.comInnovAge Holding Corp. (INNV) Reports Q1 Loss, Lags Revenue EstimatesNovember 8, 2022 | finance.yahoo.comInnovAge Announces Financial Results for the Fiscal First Quarter Ended September 30, 2022November 1, 2022 | finance.yahoo.comEarnings Preview: InnovAge Holding Corp. (INNV) Q1 Earnings Expected to DeclineSee More Headlines INNV Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INNV Company Calendar Last Earnings5/09/2023Today6/07/2023Fiscal Year End6/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Health services Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:INNV Previous SymbolNASDAQ:INNV CUSIPN/A CIK1411879 Webwww.innovuspharma.com Phone844-803-8745FaxN/AEmployees2,000Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.25 High Stock Price Forecast$9.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside-7.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,520,000.00 Net Margins-6.17% Pretax Margin-7.63% Return on Equity-13.04% Return on Assets-7.48% Debt Debt-to-Equity Ratio0.25 Current Ratio1.57 Quick Ratio1.57 Sales & Book Value Annual Sales$698.64 million Price / Sales1.53 Cash Flow$0.09 per share Price / Cash Flow84.11 Book Value$2.50 per share Price / Book3.14Miscellaneous Outstanding Shares135,630,000Free Float135,291,000Market Cap$1.07 billion OptionableNot Optionable Beta-0.01 Key ExecutivesMr. Patrick Blair (Age 52)Pres & CEO Comp: $1.48MMs. Barbara K. Gutierrez CPA (Age 60)Chief Financial Officer Comp: $625.45kMs. Nicole D'Amato (Age 44)Chief Legal Officer & Corp. Sec. Comp: $683.95kMr. Edward Moore Kennedy Jr. (Age 62)J.D., Independent Director Comp: $100kHon. Marilyn Barbour Tavenner M.H.A. (Age 72)R.N., Independent Director Comp: $120kMs. Maria Lozzano (Age 43)Chief Operating Officer Mr. Ryan KubotaDirector of Investor RelationsMs. Olivia PattonChief Compliance OfficerMs. Robin Doerr (Age 59)Chief Sales & Marketing Officer Mr. Rob BorellaChief Sales & Marketing OfficerMore ExecutivesKey CompetitorsDocGoNASDAQ:DCGOU.S. Physical TherapyNYSE:USPHSharecareNASDAQ:SHCRP3 Health PartnersNASDAQ:PIIIThe Pennant GroupNASDAQ:PNTGView All CompetitorsInsiders & InstitutionsJPMorgan Chase & Co.Bought 3,826 shares on 5/18/2023Ownership: 0.011%Geode Capital Management LLCBought 16,041 shares on 5/16/2023Ownership: 0.312%Deutsche Bank AGBought 4,268 shares on 5/15/2023Ownership: 0.009%Renaissance Technologies LLCBought 2,200 shares on 5/12/2023Ownership: 0.090%UBS Group AGBought 1,832 shares on 5/12/2023Ownership: 0.009%View All Insider TransactionsView All Institutional Transactions INNV Stock - Frequently Asked Questions Should I buy or sell InnovAge stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InnovAge in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" INNV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INNV, but not buy additional shares or sell existing shares. View INNV analyst ratings or view top-rated stocks. What is InnovAge's stock price forecast for 2023? 3 Wall Street research analysts have issued 12-month target prices for InnovAge's shares. Their INNV share price forecasts range from $5.00 to $9.00. On average, they predict the company's share price to reach $7.25 in the next twelve months. This suggests that the stock has a possible downside of 7.8%. View analysts price targets for INNV or view top-rated stocks among Wall Street analysts. How have INNV shares performed in 2023? InnovAge's stock was trading at $7.18 on January 1st, 2023. Since then, INNV stock has increased by 9.5% and is now trading at $7.86. View the best growth stocks for 2023 here. How were InnovAge's earnings last quarter? InnovAge Holding Corp. (OTCMKTS:INNV) released its earnings results on Tuesday, May, 9th. The company reported ($0.05) EPS for the quarter, hitting the consensus estimate of ($0.05). The company had revenue of $172.54 million for the quarter, compared to analyst estimates of $174.54 million. InnovAge had a negative trailing twelve-month return on equity of 13.04% and a negative net margin of 6.17%. What other stocks do shareholders of InnovAge own? Based on aggregate information from My MarketBeat watchlists, some companies that other InnovAge investors own include EEStor Co. (ESU.V) (ESU), Antares Pharma (ATRS), Federal National Mortgage Association (FNMA), Medicines (MDCO), Frontier Communications (FTR), FedEx (FDX), Republic First Bancorp (FRBK), Aytu BioPharma (AYTU), NVIDIA (NVDA) and Pacific Premier Bancorp (PPBI). What is InnovAge's stock symbol? InnovAge trades on the OTCMKTS under the ticker symbol "INNV." Who are InnovAge's major shareholders? InnovAge's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (0.94%), Geode Capital Management LLC (0.31%), Cambiar Investors LLC (0.23%), Renaissance Technologies LLC (0.09%), Martingale Asset Management L P (0.04%) and ExodusPoint Capital Management LP (0.03%). Insiders that own company stock include Edward Moore Jr Kennedy, Maureen Hewitt and Thomas Scully. View institutional ownership trends. How do I buy shares of InnovAge? Shares of INNV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is InnovAge's stock price today? One share of INNV stock can currently be purchased for approximately $7.86. How much money does InnovAge make? InnovAge (OTCMKTS:INNV) has a market capitalization of $1.07 billion and generates $698.64 million in revenue each year. The company earns $-6,520,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis. How many employees does InnovAge have? The company employs 2,000 workers across the globe. How can I contact InnovAge? InnovAge's mailing address is 8845 Rehco Road, San Diego CA, 92121. The official website for the company is www.innovuspharma.com. The company can be reached via phone at 844-803-8745 or via email at ir@innovuspharma.com. This page (OTCMKTS:INNV) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InnovAge Holding Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.